title: Targeting monocytes/macrophages in the treatment of rheumatoid arthritis.
abstract: Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches we have used to target monocytes/macrophages as major components of inflammation and bone homeostasis. We also discuss how anti-TNF-α antibodies target monocytes/macrophages in the complex mechanisms contributing to inhibition of inflammation.
authors.affiliation: UMR INSERM 1043, CPTP, CHU Purpan, Toulouse, France. jean-luc.davignon@inserm.fr
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Davignon
authors.forename: Myriam
authors.initials: M
authors.lastname: Hayder
authors.forename: Michel
authors.initials: M
authors.lastname: Baron
authors.forename: Jean-Frédéric
authors.initials: JF
authors.lastname: Boyer
authors.forename: Arnaud
authors.initials: A
authors.lastname: Constantin
authors.forename: Florence
authors.initials: F
authors.lastname: Apparailly
authors.forename: Rémy
authors.initials: R
authors.lastname: Poupot
authors.forename: Alain
authors.initials: A
authors.lastname: Cantagrel
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D050091:Dendrimers; D020868:Gene Silencing / Q000187:drug effects*; D054513:Group IV Phospholipases A2 / Q000235:genetics*; D006801:Humans; D008264:Macrophages / Q000201:enzymology*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009000:Monocytes / Q000201:enzymology*; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D050091:Dendrimers; D034741:RNA, Small Interfering; D014409:Tumor Necrosis Factor-alpha; D054513:Group IV Phospholipases A2